Brigitte Chabrol

Brigitte Chabrol

Auto-generated profile, based on publicly available information

Brigitte Chabrol

Pediatric Neurology Department, La Timone Children Hospital, APHM, Marseille, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1993 in Pediatric Neurology
Verified
Journal Article
Closed access
JMJosette Mancini
Josette Mancini
NPNicole Philip
Nicole Philip
BCBrigitte Chabrol
Brigitte Chabrol
PDPriscille Divry
Priscille Divry
MRMarie-Odile Rolland
Marie-Odile Rolland
NPNicole Pinsard
Nicole Pinsard

9 December 2022 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AGAntoine Gardin
Antoine Gardin
MCMartin Castelle
Martin Castelle
SPSamia Pichard
Samia Pichard
ACAline Cano
Aline Cano
BCBrigitte Chabrol
Brigitte Chabrol
ABAnaïs Brassier
Anaïs Brassier
Mucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8–16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n = 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy.

7 June 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AMAgathe Molimard
Agathe Molimard
CGCyril Gitiaux
Cyril Gitiaux
CBChristine Barnerias
Christine Barnerias
FAFrédérique Audic
Frédérique Audic
AIArnaud Isapof
Arnaud Isapof
IDIsabelle Desguerre
Isabelle Desguerre
Background and Objectives Corticosteroids are the first-line immunosuppressants in the management of juvenile myasthenia gravis despite their adverse effects. The place of new immunosuppressive therapies is not clearly defined by the last international consensus held in March 2019 due to the lack of clinical trials. The aim of this study is to describe the use of rituximab and its efficacy and safety in 8 main pediatric centers of the French neuromuscular reference network to propose a new place in the therapeutic strategy of juvenile myasthenia gravis. Methods We conducted a retrospective multicenter study from January 1, 2009, to April 30, 2020, including a large cohort of children with myasthenia gravis in 8 main French pediatric reference centers of the FILNEMUS network. The type of myasthenia, different lines of immunosuppressive treatment, and clinical course of the patients were collected. To evaluate the efficacy of rituximab, we studied the clinical course of patients on immunosuppressive therapy. Outcome was defined as the clinical and therapeutic status of patients at the last visit: stable without immunosuppressants, stable with immunosuppressants, or unstable. Results We included 74 patients: 18 children with ocular form and 56 children with generalized form. Of the 37 patients who required immunosuppressive therapy, 27 were treated with rituximab. Patients treated with rituximab had a better outcome than patients treated with conventional immunosuppressants (p = 0.006). The use of rituximab as a first-line immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75% of patients (vs 25%, p = 0.04) and results in cortisone sparing (42% vs 92%, p = 0.03) compared with rituximab treatment as a second- or third-line immunosuppression. Rituximab was well tolerated; no adverse effect was observed. Discussion The use of rituximab has increased in France over the last 10 years as a first-line immunosuppressant. This study suggests good tolerability and efficacy of rituximab in juvenile myasthenia gravis. Early use appears to improve outcomes and facilitate cortisone sparing in antibody-positive generalized juvenile myasthenia. Classification of Evidence This study provides Class III evidence that for children with MG, rituximab is effective and well tolerated.

1 July 2017 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
KFKonstantina Fragaki
Konstantina Fragaki
ACAnnabelle Chaussenot
Annabelle Chaussenot
ABAudrey Boutron
Audrey Boutron
SBSylvie Bannwarth
Sylvie Bannwarth
CRCecile Rouzier
Cecile Rouzier
VPVeronique Paquis-Flucklinger
Veronique Paquis-Flucklinger

1 August 2024 in Neurology Genetics
Verified
Journal Article
Open access
ARAgnès Rötig
Agnès Rötig
PGPauline Gaignard
Pauline Gaignard
GBGiulia Barcia
Giulia Barcia
ZAZahra Assouline
Zahra Assouline
CBClaire-Marine Berat
Claire-Marine Berat
MSManuel Schiff
Manuel Schiff
DNA polymerase subunit gamma (POLG) deficiency is likely the most frequent cause of nuclear-encoded mitochondrial disorders. POLG-related disorders reportedly constitute a spectrum of overlapping phenotypes from infancy to late adulthood. We retrospectively reviewed natural histories for 40 children carrying biallelic pathogenic POLG variants. The patients were identified by the French coordinating center for mitochondrial disorders (CARAMMEL), making this a large monocentric series on childhood-onset POLG deficiency. Three patterns of clinical course and survival were observed, distinguished by main category of symptoms: neurologic, hepatic, and gastrointestinal. A total of 24 patients needed urgent neurointensive care for tonic-clonic seizures, myoclonic epilepsy, and status epilepticus, occasionally precipitated by valproate administration. Other neurologic symptoms included dystonia, cerebellar ataxia, and peripheral neuropathy. We report 6 POLG-deficient patients with polyradiculoneuropathy mimicking subacute Guillain-Barré syndrome and provide postgadolinium MRI evidence of diffuse cranial nerve root and cauda equina enhancement, suggesting these disorders have an inflammatory component. Children presenting with enteral nervous system involvement had vomiting, gastroparesis, and chronic intestinal pseudo-obstruction. They had later ages of onset and lived much longer. Primarily, hepatic presentations had the earliest onset and shortest survivals. Secondary hepatic failure was frequently precipitated by valproate administration given before diagnosis to patients with focal impaired awareness seizures or absence of seizures. These POLG deficiencies were often fatal, with age at death ranging from 3 months to 10 years, with a significant difference in survival between the 3 clinical forms; 6 of the 40 children did survive. No genotype-phenotype correlations were found for the 3 clinical course types. The study demonstrates the prevalence of neurologic presentation and the extent of central, peripheral, and autonomous nervous system involvement in 60% of patients. Most of the patients with early onset and rapidly fatal hepatic failure did not live long enough to develop neurologic symptoms. The study revealed a new clinical form of POLG deficiency presenting with neurodigestive symptoms with longer lifespan. We also propose that POLG deficiency should be considered in children presenting with unexplained polyradiculoneuropathy, demyelinating neuropathy, and elevated CSF protein. Finally, valproate administration remains a notable cause of avoidable death in POLG-deficient patients.

4 December 2014 in Archives de Pédiatrie
Verified
Journal Article
Closed access
BSB. Sterling
B. Sterling
EBE. Bosdure
E. Bosdure
NBN. Stremler-Le Bel
N. Stremler-Le Bel
BCB. Chabrol
B. Chabrol
JDJean Christophe Dubus
Jean Christophe Dubus